H. A. Carlson

The paper reports on a DREAM Challenge to predict multi-target kinase inhibitors for RET-based tumors and Tauopathy, using neural network-based machine learning approaches.

This study shows AGO2 is required for pancreatic cancer progression but not initiation, with its role dependent on mutant KRAS and EGFR signaling.